LONDON (Alliance News) - Drugmaker GlaxoSmithKline PLC on Tuesday said its ViiV Healthcare arm has started a phase 3 programme to support regulatory filings for a two-drug regimen of dolutegravir and lamivudine.
The two drugs, sold at Tivicay and Epivir, are being trialled as a treatment for HIV-1 infection in adults who have not received any prior antiretroviral therapy.
"We believe the clinical profile for dolutegravir presents an important opportunity to investigate the possibility of first-line treatment of HIV with a two-drug regimen. With this ambitious phase III programme, we will explore whether this two-drug regimen can fundamentally change the existing HIV treatment strategy, reducing the number of medications and potentially streamlining treatment regimens for people living with HIV," said John Pottage, chief scientific and medical officer at ViiV.
Shares in Glaxo were down 1.2% to 1,692.24 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)